Muscle Atrophy Reversed by Growth Factor Activation of Satellite Cells in a Mouse Muscle Atrophy Model

Simon Hauerslev, John Vissing, Thomas O. Krag

Neuromuscular Research Unit, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Abstract

Muscular dystrophies comprise a large group of inherited disorders that lead to progressive muscle wasting. We wanted to investigate if targeting satellite cells can enhance muscle regeneration and thus increase muscle mass. We treated mice with hepatocyte growth factor and leukemia inhibitory factor under three conditions: normoxia, hypoxia and during myostatin deficiency. We found that hepatocyte growth factor treatment led to activation of the Akt/mTOR/p70S6K protein synthesis pathway, up-regulation of the myogenic transcription factors MyoD and myogenin, and subsequently the negative growth control factor, myostatin and atrophy markers MAFbx and MuRF1. Hypoxia-induced atrophy was partially restored by hepatocyte growth factor combined with leukemia inhibitory factor treatment. Dividing satellite cells were three-fold increased in the treatment group compared to control. Finally, we demonstrated that myostatin regulates satellite cell activation and myogenesis in vivo following treatment, consistent with previous findings in vitro. Our results suggest, not only a novel in vivo pharmacological treatment directed specifically at activating the satellite cells, but also a myostatin dependent mechanism that may contribute to the progressive muscle wasting seen in severely affected patients with muscular dystrophy and significant on-going regeneration. This treatment could potentially be applied to many conditions that feature muscle wasting to increase muscle bulk and strength.

Citation: Hauerslev S, Vissing J, Krag TO (2014) Muscle Atrophy Reversed by Growth Factor Activation of Satellite Cells in a Mouse Muscle Atrophy Model. PLOS ONE 9(6): e100594. doi:10.1371/journal.pone.0100594

Editor: Antonio Musaro, University of Rome La Sapienza, Italy

Received January 22, 2014; Accepted May 29, 2014; Published June 25, 2014

Copyright: © 2014 Hauerslev, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Lundbeck Foundation grant #R9-A783 (http://www.lundbeckfonden.com), Aase og Ejnar Danielsen Fond #106179 (http://www.daniensensfond.dk), AP Møller Foundations #070126,080140 (http://www.apmøllerfonde.dk), and The Research Council at Rigshospitalet. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Introduction

Muscular dystrophies comprise a large group of inherited disorders that lead to progressive muscle wasting. Much effort has been put into finding a cure or a treatment that alleviates the deficient motor function in these patients. Despite these efforts, no effective cure has yet been found against any of the muscular dystrophies, although viral delivery of the gene at issue and antisense oligonucleotide-mediated exon skipping have been attempted for many years. While such therapies can be adapted to treat a variety of different muscular dystrophies, these approaches are limited by technical issues related to 1) problems in delivering the gene to all affected cells and 2) development of an immune response against the protein or the vector harboring the gene for the missing protein, if the patient is completely devoid of the protein product in question. If possible, an approach that uses a compound known to the immune system of the patient would be preferable. Several approaches aimed at generating a larger muscle mass have been reported in the past decade, among them IGF-1 therapies and myostatin-inhibition [1,2]. However, there are potentially other ways to induce hypertrophy or muscle repair. This could be accomplished by utilizing an already existing and highly efficient repair mechanism, the satellite cells, which are muscle specific stem cells. The satellite cells are quiescent in normal adult muscle, but activated in response to diverse stimuli such as injury, denervation, exercise, or stretching [3]. The mechanisms of satellite cell activation, proliferation, and migration have been well examined. HGF is the only known factor that is capable of activating satellite cells through the c-Met receptor [4,5]. Activation of satellite cells lead to myoblast proliferation and terminal differentiation and fusion [6,7]. HGF is present in uninjured myofibers and upon muscle injury may be secreted from them to the extracellular matrix surrounding myofibers and quickly acts on the satellite cell pool [5]. After satellite cell activation, expression of muscle regulatory factors, Myf5 and MyoD occurs, and at the beginning of differentiation, myogenin and MRF4 are expressed [8]. When HGF binds to the c-Met receptor tyrosine kinase, its cytoplasmic Tyr residues are autophosphorylated and bind the scaffolding adaptor protein Gab1, which leads to the activation of phosphatidylinositol 3-kinase (PI3K) and Ras-ERK mitogen-activated protein kinase cascade (Fig. 1) [9]. This suggests that controlled activation of c-Met signaling can be exploited in regenerative medicine. HGF is a well-known activator of satellite cells through the c-Met receptor, and there have been numerous in vitro experiments confirming that it activates satellite cells [5,10]. However, it has also been reported that HGF delivered by intra-muscular injections inhibits differentiation in mice, which had been subjected to freeze injury and that repeated injections of HGF inhibited regeneration. This could be a matter of timing, as new injections may not have any effect before the effect of the preceding HGF injection had subsided. The choice of delivery method may also lead to a too high local concentration of HGF in the needle tract, leading to saturation of available receptors and ultimately premature initiation of a negative feed-
back signal. This could render satellite cells insensitive to further HGF injections unless the time between injections was increased [4]. When designing our protocol, we took this into consideration, and used intra-peritoneal injections rather than intra-muscular, which may yield a more even concentration of exogenous HGF in the muscles.

Leukemia inhibitory factor (LIF) is known to stimulate myoblast growth and fusion in vitro by receptor-mediated mechanisms [11,12]. LIF acts directly at the site of injury and stimulates hypertrophy of the muscle fibers rather than hyperplasia [11–13]. In this study, we demonstrate that HGF-mediated activation of the satellite cells in hypoxia-induced muscular atrophy combined with LIF can reverse the loss of muscle mass. Rather than using normal mice under normoxic conditions, we use a hypoxia-induced atrophy model to enhance the effect of the treatment, since satellite cells are more prone to become activated under hypoxic compared to normoxic conditions [14,15].

Materials and Methods

Animals

Only male mice were used for this study. C57BL/10ScSn bred at the animal facility at the University of Copenhagen and Mstn ln/ln mice (strain #9345) were purchased from Jax mice. Control and treated mice were housed in separate cages (a maximum of 6 animals per cage) containing activity stimulating toys, at a 12:12-h light-dark cycle and 22°C ambient temperature and received rodent chow (Lab Diet 5001) and water ad libitum. All mice included in this study were aged 15–16 weeks at the beginning of experiments. To perform the time-course study under normoxia following a single HGF injection, twenty-three C57BL/10ScSn mice were included. A second cohort of twenty-three C57BL/10ScSn mice were randomly assigned to a single HGF-treated group (n = 11 mice) or a PBS-treatment control group (n = 12 mice), and were exposed to 17 days of hypoxia. A third cohort of twenty-seven C57BL/10ScSn mice were randomly assigned to multiple treatments with HGF/LIF (n = 13 mice) or PBS-treated control group (n = 14 mice) and were exposed to 4 weeks of hypoxia. Finally, 16 Mstn ln/ln mice (strain #9345, purchased from Jax mice) and 16 C57BL/10ScSn mice were studied under normoxic conditions and received same treatment as the hypoxic mice.

Ethical statement

This study was carried out in strict accordance with Danish law and all experiments were approved by the Danish Animal Experiments Inspectorate (Permit number 2012-15-2934-00595). All efforts were made to minimize suffering.

Hypoxic protocol

In order to create a muscle atrophy model, we let the mice stay in a chamber with a gradually more hypoxic atmosphere starting at 12% until it reaches approx. 7.5% at day 7 simulating an ascent to an altitude of approximately 8,200 m above sea level (calculated from http://www.altitude.org). At day 2 the oxygen level was reduced from 12% to 10%, at day 4 further to 9% and at day 6 to 8%, by reducing the oxygen and increasing the nitrogen flow using flow meters to mix the gas, which entered the chamber at 3.0 l/min and exited through an one-way valve. The custom made normobaric hypoxic chamber had a volume of 85 litres and was maintained at 22°C and 45% humidity. Oxygen, carbon dioxide, temperature and humidity levels were monitored using sensors and a data logger (ScienceScope, Radstock, UK). To allow for visual inspection of health and condition of the mice during the light cycle, we installed a 360°/180° web-cam with a high-power zoom (BB-HMC581CE, Panasonic, Osaka, Japan) that could be remotely controlled by a PC or smartphone. Mice were briefly removed from the hypoxic chamber every second day so that cage
bedding could be changed, water and chow consumption measured, and mice could be weighed and receive injections.

After two weeks of hypoxic exposure, treatment started with recombinant mouse HGF (2207 HG/CF; R&D Systems, Minneapolis, MN) 20 ng/g body weight, followed 2 days after by recombinant mouse leukemia inhibitory factor (L5158, Sigma-Aldrich, St Louis, MO) 10 ng/g body weight by intraperitoneal injections for systemic delivery. Each injection contained BrdU (B5002, Sigma-Aldrich, St. Louis, MO) 10 ng/g body weight. Mice were euthanized by cervical dislocation, and tibialis anterior (TA) and extensor digitorum longus (EDL) muscles of the lower limb were dissected. Muscles were trimmed of excess connective tissue, blotted dry, and weighed and then immediately flash frozen in isopentane cooled in liquid nitrogen and stored at −80°C.

**Immunohistochemistry and Histology**

Cryo-sections of EDL were cut every 1 mm to determine the midbelly cross-sectional area of the EDL muscle. Sections were stained with hematoxylin and eosin for general histopathological evaluation, cross-sectional area and assessment of internally nucleated fibers (INF). For immunohistochemistry sections were fixed in 10% normal buffered formalin and subsequently blocked in buffer (5% normal goat serum in PBS) prior to staining. To assess the number of satellite cells undergoing divisions, sections were incubated with Pax7 (DSHB) diluted 1:100 and Ki67 (#15580, Abcam, Cambridge, UK) antibodies diluted 1:500. Positive nuclei were confirmed by DAPI nuclear stain (Invitrogen, Carlsbad, CA) and to be in a satellite cell position under the basal lamina by using an antibody against laminin (L9393, Sigma-Aldrich, St Louis, MO). To assess the number of cells with DNA synthesis since beginning of treatment, sections were incubated with BrdU antibody (clone G3G4, DSHB) diluted 1:500 and DAPI nuclear stain (Invitrogen, Carlsbad, CA). Active regenerating myofibres were visualized using embryonic myosin heavy chain (F1.652, Vector Laboratories, Burlingame, CA) diluted 1:100. Alexa 488 and 594 (Invitrogen, Carlsbad, CA) secondary anti-mouse and anti-goat antibodies were used at a 1:500 dilution in PBS buffer. The sections were observed under a Nikon 80i microscope with epi-fluorescence. Area of EDL was measured using NIS-Elements Basic Research software (Nikon Instruments, Melville, NY).

**MR scanning**

Whole body composition was analyzed without anesthesia or restraint by an EchoMRI 4-in-1 scanner (EchoMRI, Houston, TX) before and after 4 wk exposure to hypoxia. The scanner assessed fat mass, lean tissue mass, free fluids, and total body water content as independent characteristics. By freeze-drying the tibialis anterior muscle, water content was calculated during normoxia and after the hypoxic protocol.

**RT-qPCR**

Muscle samples were collected over a six month period and stored at −80°C. RNA from TA muscles was extracted using TriZol i biologically duplicates and resuspended in RNA storage solution (AM7000, Invitrogen, Carlsbad, CA). All primers (Sigma-Aldrich, St Louis, MO) in this study were designed for unique transcripts using Primer-Blast [http://www.ncbi.nlm.nih.gov], to produce amplicons of 70–150 base pairs and to be exon-spanning (see Table S1 for primers). DNase I treatment of samples was therefore omitted. UNAFold 3.8 software was used to analyze the primers for potential secondary structures that may prevent efficient amplification. Primers were tested for efficiency (E) by serial dilution of cDNAs and primers were only accepted for use if 1.9 ≤ E ≤ 2.1. Purity of RNA samples with respect to protein and phenol contamination and concentration was assessed using a spectrophotometer (NanoDrop 2000, Thermo Scientific, Waltham, MA), and all samples had an OD260/280 of 1.8–2.0, indicating that purity of mRNA was acceptable. RNA integrity was analyzed using the automated microfluidics-based electrophoresis system 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). All RNA samples had RIN values above 7 (mean 8.5 ± 2.0) and a 20/18S ratio between 1 and 2 indicative of an intact RNA sample. 300 ng RNA were converted into cDNA by reverse transcription using iScript (Bio-Rad, Hercules, CA).

Twenty μl reactions with SsoFast EvaGreen master mix (Bio-Rad, Hercules, CA) were amplified using a CFX96 RT-qPCR instrument (Bio-Rad, Hercules, CA). The melt curve analysis always displayed a single sharp peak thus confirming specificity of primer annealing and by running an agarose gel confirming the expected amplicon size. An inter-run calibrator, a no template control (NTC) reaction and a no reverse transcriptase (NRC) reaction were included in every run. NTC and NRC reactions were always below Cq<38. Results were analyzed and reference genes chosen using qBase Plus 2.0 software (Biogazelle, Zwijnaarde, Belgium).

**Western blotting**

TA muscles were homogenized in ice-cold lysis buffer with protease and phosphatase inhibitors (10 mM Tris, pH 7.4, 0.1% Triton-X 100, 0.5% sodium deoxycholate, 0.07 U/ml aprotinin, 20 μl leupeptin, 20 μl pepstatin, 1 nM phenylmethylsulfonyl fluoride (PMSF), 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 5 mM β-glycerophosphate, 1 mM sodium fluoride, 1.15 mM sodium molybdate, 2 mM sodium pyrophosphate decahydrate, 1 mM sodium orthovanadate, 4 mM sodium taurocholate, 2 mM imidazole, 10 mM calcium, 5 μM cantaridin) using a bead-mill at 4°C. Supernatants were collected and protein concentrations were determined using the Bradford assay. Equal amounts of extracted muscle proteins were separated on 10% TGX polyacrylamide gels (Bio-Rad, Hercules, CA) at 200V for 30 min. Proteins were transferred to PVDF membranes and post transfer membranes were stained with Sypro Ruby (Sigma-Aldrich, St Louis, MO) to ensure equal protein transfer. Membranes were blocked in Baileys Irish Cream (Dublin, Ireland) for 30 min and incubated overnight with primary antibodies (4E-BP1 (Thr37/46); Akt (Ser473); Akt; eIF4E (Ser209); mTOR (Ser2448); p70S6K (Thr389); p70S6K; PDK1 (Ser241); P38K (Tyr458/p65)/Tyr199/p55); Ubiquitin (P4D1) from Cell Signaling Technologies, Danvers, MA; N-Tubulin (12G10) and Myogenin (F5D), (Developmental Studies Hybridoma Bank, Iowa City, IA); Myostatin (AB3239, Millipore, Billerica, MA), MAFbx and MuRF1, (Sigma-Aldrich, St Louis, MO), MyoD1 (5.8A, Vector Laboratories, Burlingame, CA). Secondary antibodies coupled with horseradish peroxidase diluted 1:10000 were used to detect primary antibodies (DAKO, Denmark). Immuno-reactive bands were detected using a SuperSignal West Dura kit (Thermo Scientific, Waltham, MA), quantified using a GBox XT16 darkroom and GeneTools software (Syngene, UK) was used to measure the intensity of immune-reactive bands on 16-bit digital photos. Immuno-reactive band intensities were normalized to the intensity of the N-Tubulin bands for each subject to correct for differences in total muscle protein loaded on the gel. For Akt (Ser473) and p70S6K (Thr389) these targets were calculated and shown as ratios of total Akt and p70S6K respectively.
Significant difference between treated animals and controls. A p-comparison to hypoxic mice injected with PBS (3% group compared to hypoxic controls, and compared to normoxia, treatment of normoxic mice

Protein synthesis and myogenic signaling following HGF treatment of normoxic mice

To investigate the mechanistic effect of treatment with HGF we first performed a 0-48-hour time-course study in normoxic mice. Following a single injection with HGF, we found an increased activity of the Akt/mTOR/p70S6K pathway involved in protein synthesis within the first hour, and an elevation in myogenic factors MyoD and myogenin after 24–48 hours (p<0.05) (Fig. 2). To test if the response to HGF could be enhanced by increasing the dose, we treated animals with a 10 times higher dose (200 ng HGF/g body weight), and the mice were then sacrificed after one hour. We found a reduced response in activation of p70S6K compared to the low dose group at the same time point (Fig. 2E). Performing RT-qPCR analysis on the time-course samples, we found that the elevation of protein expression of myogenin was mirrored in the mRNA response (Fig. 3). MyoD and myostatin mRNA were increased after 3 hours, while MuRF1 was increased after 48 hours.

HGF/LIF treatment of hypoxia-induced muscle atrophy leads to increased muscle mass

To investigate if this treatment could have an effect on muscle atrophy, we used hypoxia to induce muscle atrophy. B10 mice were exposed to 2 weeks of hypoxia before starting treatment. Hypoxia was continued during treatment with HGF/LIF (N=13) or placebo (N=14) (Fig. 4d). Quantitative MRI confirmed that body weight loss during the four weeks of exposure to hypoxia did not alter whole body composition (Fig. 4B). Subsequently, we determined muscle wet weight and then freeze-dried the tibialis anterior (TA) muscles in vacuum to investigate if muscle weight loss obtained during the four weeks of exposure to hypoxia was caused by altered muscle water content. Based on dry weight; wet weight ratio in TA in normoxia (0.24±0.01) and after the hypoxia protocol (0.25±0.01) muscle water content was unchanged (P<0.13) (Fig. 4C). We also found that hypoxia induced loss of muscle protein measured as total soluble protein in muscle homogenates per wet weight (P<0.03) (Fig. 4D). Exposure to hypoxia for four weeks resulted in a significant (P<0.01) 18% decrease in body weight (Fig. 5A). There was no significant difference in either food nor water intake between groups (Fig. 5B and C). There was no significant difference in body weight between groups at the beginning of the experiment (31.4±1.5 and 31.6±2.2 g for PBS- and HGF/LIF-treated mice, respectively, P<0.05) or at the end (26.1±1.8 and 25.3±2.1 g for PBS- and HGF/LIF-treated mice, respectively, P<0.03) (Fig. 5A and D). Alternating treatment of atrophic mice with HGF and LIF significantly increased muscle mass of both TA (9%, P<0.02) and extensor digitorum longus (EDL) (18%, P<0.003) compared to control mice during exposure to hypoxia (Fig. 5E and F). Correspondingly, the cross-sectional area of EDL increased 22% (P<0.001) in the HGF/LIF treated group compared to hypoxic controls, and compared to normoxia, atrophy was reversed (P<0.09) in the HGF/LIF treated group (Fig. 5G). Satellite cells undergoing divisions were 3-fold increased in hypoxic mice treated with a single HGF injection (9%±3%) compared to hypoxic mice injected with PBS (3%±1%) (Fig. 6A and C). Repeated alternating injections with LIF/HGF increased the replicative response (59±28 BrdU/nuclei/mm²) compared to hypoxic mice injected with PBS (9±2 BrdU/nuclei/mm²) (P<0.01) (Fig. 6B and D).

Repeated alternating injections with LIF/HGF in hypoxic mice showed that these growth factors trigger the activation of factors involved in protein synthesis (PDK1, 4E-BP1 and eIF4E; Fig. 7A, B and C). The activation levels of other factors in this signaling pathway were not significantly changed (PI3Kα/ε, p70S6K and p70S6K, Fig. 7D, E and F). mRNA levels for MyoD and myogenin were not significantly different between PBS and HGF/LIF treated hypoxic mice. However, the myostatin pathway for growth control as well as protein degradation in terms of MAFbx was significantly elevated in the HGF/LIF treated hypoxic mice (Fig. 8C and D). We found no significant difference in the mRNA level of MuRF1 in HGF/LIF treated mice versus controls (Fig. 8E).

Myostatin represses HGF/LIF treatment in normoxic mice and controls protein degradation

We wanted to determine if there was a mechanism linking myostatin to MAFbx- and MuRF1-related protein degradation in vivo. For this purpose, we carried out HGF/LIF treatment of Mstnln/ln and wild-type mice under normoxic conditions as with the time-course experiment since myostatin-mediated growth-repression is probably more active under normal conditions (Fig. 3). Muscle weight of both TA and EDL normoxic was increased 40% in Mstnln/ln compared to wild-type mice (Fig. 9A and B). Treatment with HGF/LIF resulted in 7% increase in TA muscle weight compared to control group in Mstnln/ln mice (P<0.04), but not in normoxic wild-type mice (Fig. 9A). While there was no significant difference in levels of myostatin in B10 mice treated with alternating injections of HGF/LIF compared to controls, we found that HGF/LIF in Mstnln/ln mice lead to a very significant down-regulation of MAFbx and MuRF1 (Fig. 9C-E). This is further supported by the significant decrease in ubiquitinylated proteins in the HGF/LIF treated Mstnln/ln mice compared to the PBS treated Mstnln/ln mice (P<0.003) (Fig. 9F). Treatment with HGF/LIF resulted in a 6-fold more mitotically active state in normoxic Mstnln/ln vs. wild-type mice satellite cells (Fig. 10A). Expression of MyoD mRNA showed no difference among groups, whereas myogenin mRNA increased 10-fold in treated Mstnln/ln mice compared to Mstnln/ln injected with PBS (Fig. 10B and C). Transcription of myogenin was 3-fold increased in treated Mstnln/ln mice compared to treated wild-type mice (Fig. 10C). Treating normoxic Mstnln/ln mice with HGF/LIF did not lead to negative growth control, unlike in wild-type normoxic mice, where the myostatin pathway for growth control appears induced, consistent with our observations during hypoxia (Fig. 10D-F).

Discussion

Two decades following the cloning of the dystrophin gene, the gene involved in Duchenne muscular dystrophy (DMD), much effort has been put into finding a cure or therapy that alleviates symptoms. Generally speaking, these approaches can be divided into two categories; those that attempt to rectify the causative problem, i.e. targeting the dystrophin gene, and those that in a more general way aim to repair or replace damaged tissue by more unspecific stimulation of regeneration. In the present study, we have chosen a strategy that aims at balancing the degeneration – regeneration cycle, which in muscular dystrophies is skewed towards degeneration, thus leading to a progressive loss of muscle mass. In this study, we have demonstrated the following novel
findings: 1. HGF treatment in vivo leads to up-regulation of the Akt/mTOR/p70S6K protein synthesis and hypertrophy pathway.
2. HGF/LIF can reverse atrophy through activation of the satellite cells.
3. The efficiency of the treatment appears to be inversely related to myostatin-dependent protein degradation. For patients who are suffering from muscle loss/wasting, in whom the regenerative capacity of muscles is unaffected, HGF/LIF and a myostatin-inhibitor could potentially be a new treatment that can boost muscle regeneration, and reverse muscle atrophy.

We wanted to investigate how HGF affects protein synthesis over time by treating mice with HGF under normoxic conditions. Our results demonstrate that HGF in vivo rapidly leads to activation of the protein synthesis pathway and subsequent up-regulation of MyoD and myogenin. Interestingly, treating mice with a 10 times higher dose of HGF resulted in a poorer activation of the protein synthesis pathway, suggesting that a high concentration of HGF may inhibit rather than activate the protein synthesis pathway, which has also been suggested recently [16]. A simpler explanation could be that HGF at the 20 ng/g body weight concentration we administered is sufficient to saturate the available c-met receptors of the quiescent satellite cells. After all, there are a finite number of quiescent satellite cells and it is debatable if all subpopulations of satellite cells respond in the same way to HGF. However, as the kinetics of HGF in vivo is not well understood this remains speculation. While the HGF time course results were encouraging, our qPCR data from the above experiment suggests that a down-stream effector of HGF activates a negative feedback mechanism acting through myostatin, which regulates growth negatively [16].

We demonstrated that HGF leads to an increase in MyoD mRNA 3 hours post-injection and a peak in MyoD protein after 24 hours. In line with the RNA expression, the protein expression levels of MyoD and myogenin also increased. Concurrently, at 3 hours, possibly later, but before 24 hours post-injection, myostatin mRNA peaked as well. Previous studies have established that MyoD is one of the key transcription factors regulating...
Figure 3. Hepatocyte growth factor increases mRNA expression of myogenic factors and myostatin. Total RNA was purified from the same samples as used in figure 2. RT-qPCR analysis of mRNA expression levels in tibialis anterior shows hepatocyte growth factor increases myogenic factors MyoD, myogenin (A,B). Muscle negative regulation and protein breakdown pathway myostatin, MAFbx and MuRF1 (C-E) were increased following a single injection with hepatocyte growth factor. RU = Relative Units. N = 3 for all time points, except for 60 minH (= a 10 times higher dose of hepatocyte growth factor [200 ng HGF/g body weight] sacrificed after 60 min) where N = 2. Error bars are SD; One-way ANOVA with Bonferroni post hoc correction for multiple comparisons was used to assess differences among groups for each dependent variable. *denotes significant (P<0.05). Data are representative of four independent experiments.
doi:10.1371/journal.pone.0100594.g003

Figure 4. The hypoxic protocol and verification of atrophy model. In order to create a muscle atrophy model, we let the mice stay in a chamber with a gradually more hypoxic atmosphere until it reaches approx. 7.5%. Oxygen content in the hypoxic chamber was monitored during the hypoxic protocol (A) and time points for alternating intraperitoneal injections (B) with hepatocyte growth factor = H and leukemia inhibitory factor = L (B). Hypoxia did not change body composition (Lean/fat) measured by quantitative MRI of PBS-injected normoxic mice (N = 8, light blue), PBS-injected hypoxic mice (N = 8, dark blue) (B). Hypoxia did not change muscle water content based on dry weight: wet weight ratio in tibialis anterior (TA) of PBS injected normoxic mice (N = 8, light blue), PBS injected hypoxic mice (N = 8, dark blue) (C). Hypoxia induced loss of muscle protein measured as total soluble protein in muscle homogenates per wet weight of PBS-injected normoxic mice N = 8 (light blue) and PBS injected hypoxic mice (N = 8, dark blue) (D). Error bars are SD; Statistical significance was determined by a two-tailed Student’s t-test. *denotes significant (P<0.05). Data are representative of one independent experiment.
doi:10.1371/journal.pone.0100594.g004
myostatin expression, presumably as a negative feedback mechanism, and that myostatin subsequently is capable of repressing MyoD expression through SMAD3, part of the TGFβ-family/SMAD signaling pathway [17,18]. Akt represses expression of the muscular atrophy inducing E3-ubiquitin ligases MAFbx and MuRF1 through phosphorylation of FoxO transcription factors [19] and conversely the repressive action of Akt on MAFbx and MuRF1 can be lifted by myostatin through SMAD2 [20,21]. From 3 to 24 hours post-injection, Akt-activity decreased, presumably due to myostatin-mediated SMAD2/3 inhibition [20]. Consistent with this, we saw an increased expression of MAFbx and MuRF1 at 24 and 48 hours post-injection, confirming a previous in vitro study where HGF lead to myostatin up-regulation and increased MAFbx and MuRF1 expression 48 hours after injection of HGF [22]. The specific role of MAFbx and MuRF1 in this context is not fully known, but as MAFbx is suggested to target signaling pathways rather than structural components, and MuRF1 can interact with myosin heavy chain and the giant sarcomeric protein titin, it is possible that they down-regulate signaling pathways and remove temporary or immature elements no longer needed for the myogenic process to proceed [23]. The fact that myogenin mRNA and protein peaked at 48 hours post-injection is consistent with the above, since the need for proliferation may have abated and the myostatin-pathway has switched off further activation and proliferation leading to a cellular focus on terminal differentiation and fusion with the myofibers.

Under normal condition, the effect of HGF treatment on various morphological and physiological properties may be too subtle to allow proper analysis, unless the treatment is delivered over the course of several months. For this reason we chose to use a hypoxia-induced atrophy model to prove conceptually if treatment of atrophic/dystrophic muscle with HGF had any effect on activation of satellite cells and gain of muscle mass based on our data on increased HGF-induced protein synthesis. The use of an atrophy mouse model for evaluating the efficacy of a therapy has been described previously, in a study where treatment with soluble activin receptor IIb was demonstrated to counteract the hypoxia-induced atrophy of muscles [24].

We combined multiple HGF injections with LIF to enhance proliferation and differentiation of satellite cells. Due to the relatively short period of treatment, we did not expect and did not achieve any increased body weight in HGF/LIF treated hypoxic mice. However, it is clear that HGF/LIF leads to increased muscle mass as demonstrated in both TA and EDL. Our results also suggest that there may be an upper limit to the treatment efficiency as multiple HGF and LIF treatments did not lead to
more mitotic satellite cells than could be achieved by one HGF injection, which is consistent with earlier findings [4]. Interestingly, we found no difference in the number of mitotic satellite cells when comparing the group that had one injection of HGF/LIF to the group that had received six injections. As the number of quiescent satellite cells are considered fairly constant, our results suggest, that either the administered HGF had activated a maximum of quiescent satellite cells or activated a negative feedback loop aborting the activity of more HGF within a limited period of time.

There are likely some inherent limitations to the actions of HGF. It acts a switch, so that once the satellite cell is activated there is a turn-around time for the activated and dividing satellite cells before they enter the G0-phase again, expressing c-met receptors. In addition, HGF requires heparan-sulfate proteoglycans (HSPG) as co-receptors with the level of sulfation determining the activity of the growth factor [7]. The sulfation is regulated by Sulf1, a sulfatase, which itself becomes up-regulated as satellite cells become activated, presumably as an extracellular negative feedback preventing an overextension of the regenerative system [25]. This means that additional HGF may not be useful even though the satellite cells have entered the G0-phase, as the Sul1 must be down-regulated before proper sulfation of the HSPG can be attained as required by HGF. When this has happened, HGF may have cleared the body. The up-regulated myostatin may be an additional factor suppressing an increase in mitotic satellite cells in mice that had received multiple HGF/LIF injections, as myostatin not only effectively represses MyoD dependent activation of satellite cells, but also blocks proliferation by modulation of the cell cycle progression through p21 [26]. Hence, myostatin negatively regulates the G1 to S progression, and thus maintains the quiescent status of satellite cells. However, while up-regulation of p21 inhibits proliferation, it also promotes differentiation [27].

A positive change in activation of satellite cells and gain of muscle mass is considered beneficial for treating muscular dystrophies. After the HGF/LIF treatment, we found that cross-sectional area and weight of EDLs in HGF/LIF treated hypoxic...
animals were not significantly different from the EDLs of normoxic animals. In other words, the EDLs had recovered due to the treatment. This finding is supported by an increase in dividing satellite cells and parts of the protein synthesis signaling. However, as we saw no significant difference in the levels of MyoD and myogenin in between treated and untreated hypoxic animals and normoxic controls, we found that myostatin and MAFbx, but not MsrF1, were increased in the HGF/LIF treated hypoxic animals. Clearly there is a connection between satellite cell activation/proliferation through HGF, a rise in myostatin, MAFbx and subsequent suppression of MyoD and myogenin.

The myostatin signaling in the time-course treatment of mice with HGF as well as the increased level of myostatin in the HGF/LIF treated hypoxic mice lead us to investigate how myostatin affects HGF treatment. Consistent with our findings from the time-course experiment, we found that HGF/LIF-treated Mstnln/ln mice have a 5-fold higher level of mitotic satellite cells under normoxic conditions compared to PBS control (C57BL/10 and Mstnln/ln mice) and C57BL/10 mice treated with HGF/LIF. It is evident from these observations that myostatin very effectively represses satellite cell activation. In addition, we found that the level of mitotic satellite cells is approximately 3 times higher in atrophic mice exposed to hypoxia compared to that in normoxic mice treated with just PBS (controls). This is supported by previous findings in vitro where a hypoxic environment had a positive effect on satellite cell proliferation and differentiation [14,15]. Consistent with this, the level of myogenin in HGF/LIF-treated Mstnln/ln mice is approximately 3 times higher than in HGF/LIF-treated C57BL/10 mice, since myostatin is not around to exert its repressive influence on MyoD expression, one of the key myogenic factors that regulate myogenin expression [17]. However, the MyoD expression could have peaked before the time point at which the mice were sacrificed in our study, so our MyoD results cannot confirm this. The level of MAFbx and MsrF1 did decrease significantly in HGF/LIF-treated Mstnln/ln mice in contrast to HGF/LIF-treated C57BL/10 mice. This confirms that MAFbx and MsrF1 expression evidently is dependent on the level of myostatin, albeit not directly, but likely through inhibition of Akt as discussed in the preceding paragraphs. The decrease in structural protein related MsrF1 and ubiquitinylated proteins may explain the modest but significant increase in TA muscle mass and the significant decrease in ubiquitinylated proteins.

We have noted that HGF/LIF treatment is not dependent on damaged myofibers to be effective in vivo. This is consistent with the published in vitro experiments involving HGF treatment of myoblasts [10], but also implies that treatment with HGF/LIF at the initial dose we gave likely does not depend on a certain level of endogenous co-factors or timing in relation to cellular events. In many ways, the actions of HGF resemble the hypertrophy induced by IGF-1 growth factor, which through its receptor tyrosine kinase is capable of activating the mTOR/p70S6K protein synthesis pathway [20]. At this time, we do not know what the initiation of protein synthesis implies, since it appears to peak at 1 hour post-injection and returns to basic level after 48 hours. It is possible that protein synthesis at this stage merely means expression of MyoD and myogenin, followed by a complicated web of crossing intra-cellular signaling events eventually leading to post-48 hours expression of sarcomeric proteins.

Our results demonstrate a significant effect of HGF/LIF treatment, however, it appears obvious, based on our results from the Mstnln/ln mice, that treating animals with myostatin inhibiting factors in addition to HGF/LIF may yield an even better effect. It would be reasonable to expect an attenuation of the myostatin-dependent repression of MyoD that is evident even in HGF/LIF-treated animals, and lead to an increase in muscle mass [2].

While we have used normoxic mice for the mechanistic studies and a hypoxia-induced atrophy model for a gain of function through increased muscle mass, the relevance of the latter model for human muscular atrophies and dystrophies can be argued. However, hypoxemia in patients with Duchenne muscular dystrophy (DMD) is well documented [29], and research using animal models of DMD suggests that respiratory insufficiency
leads to a chronic hypoxic state in the muscles, which to some extent probably can be attributed to the accompanying cardiomyopathy [30–33]. The known and unknown changes in muscle function/molecular signaling is the main reason we decided not to use the DMD mdx mouse model for this study as the mechanics of HGF/LIF treatment may very well have been obscured by the mdx phenotype, thus defeating the main aim of this study [34]. We believe that the HGF/LIF therapy approach could prove beneficial to many muscular dystrophies and conditions leading to muscular atrophy as long as the primary defect is not affecting the muscle regeneration, which we have demonstrated is the case in some patients with limb-girdle muscular dystrophy type 2A (calpainopathy) [35]. Also, we have recently demonstrated that severely affected patients with limb girdle muscular dystrophy type 2I (fukutin-related protein deficiency) have a significant ongoing regeneration of muscle and increased levels of myostatin and MAFbx and MuRF1 [36,37]. A compound therapy with HGF/LIF and myostatin inhibitors may attenuate some of the adverse effects of regeneration-mediated myostatin up-regulation and let the regeneration run its due course with an attenuated level of protein degradation. In fact, a premature initiation of the myostatin-mediated protein degradation as presented in this study may in part explain why patients with severe muscular dystrophy and significant ongoing regeneration still experience progressive muscle wasting. The fact that the therapy is independent of the condition, but only depends on the ability to activate satellite cells, the inherent down-stream amplification of growth factor activation signals and the circumvention of immune response issues, makes it

Figure 9. Alternating hepatocyte growth factor and leukemia inhibitory factor treatment increases muscle mass and decreases protein breakdown pathway in normoxic myostatin deficient mice. Alternating injections of normoxic B10 mice with hepatocyte growth factor and leukemia inhibitory factor (N = 8, yellow) did not change wet weight muscle mass of Tibialis anterior = TA and extensor digitorum longus = EDL (compared to PBS injected mice (N = 8, light blue) (A,B). Alternating injections of normoxic Mstnln/ln mice with hepatocyte growth factor and leukemia inhibitory factor increased TA muscle weight compared to PBS injected Mstnln/ln mice (N = 8, light grey). Western blot data of tibialis anterior homogenates (C-F) showed no change in muscle negative regulation and protein breakdown pathway (myostatin, MAFbx, MuRF1 and ubiquitin) after repeated alternating injections with HGF/LIF in normoxic B10. Repeated alternating injections with HGF/LIF in Mstnln/ln mice decreased expression of protein breakdown pathway MAFbx, MuRF1 and ubiquitin (D-F). RU = Relative Units. Statistical significance was determined by a two-tailed Student’s t-test. *denotes significant (P<0.05). Data are representative of one independent experiment. doi:10.1371/journal.pone.0100594.g009
attractive seen from a treatment perspective. Further studies of HGF/LIF treatment of dystrophic animals under normoxic conditions will reveal if the beneficial effect of the therapy extends to these animals.

Supporting Information

Table S1  Table S1 describes the primer sequences used for qPCR as well as size of amplicon and annealing temperature.

(DOCX)
Muscle Atrophy Reversed by Growth Factors

Author Contributions
Conceived and designed the experiments: SH TOK. Performed the experiments: SH TOK. Analyzed the data: SH TOK. Wrote the paper: SH JV TOK.

References

1. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, et al. (1992) Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J 282: 91–97.

2. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whitmore LA, et al. (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420: 418–421. 10.1038/nature01154 [doi];nature01154 [pii].

3. Grounds MD, White JD, Rosenthal N, Bogoyevitch MA (2002) The role of stem cells in skeletal and cardiac muscle repair. J Histochern Cytochem 50: 589–610.

4. Miller KJ, Thaloor D, Matteson S, Pavlath GK (2000) Hepatocyte growth factor affects satellite cell activation and differentiation in regenerating skeletal muscle. Am J Physiol Cell Physiol 278: C174–C161.

5. Tatsurni R, Anderson JE, Newored CJ, Halevy O, Allen RE (1998) HGF/SF is present in normal adult skeletal muscle and is capable of activating satellite cells. Dev Biol 194: 114–128.

6. Sheehan SM, Allen RE (1999) Skeletal muscle satellite cell proliferation in response to members of the fibroblast growth factor family and hepatocyte growth factor. J Cell Physiol 181: 499–506.

7. Villena J, Brandon E (2004) Dermatan sulfate exerts an enhanced growth factor response on skeletal muscle satellite cell proliferation and migration. J Cell Physiol 198: 169–178.

8. Cornelison DD, Wold BJ (1997) Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev Biol 191: 270–283.

9. Trusolino L, Bertotti A, Comoglio PM (2010) MET signaling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11: 834–846.

10. Allen RE, Sheehan SM, Taylor RG, Kendall TL, Rice GM (1995) Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. J Cell Physiol 165: 307–312. 10.1002/jcp.1041650211 [doi].

11. Barnard W, Bower J, Brown MA, Murphy M, Austin L (1994) Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle expresses Lif mRNA. J Neurol Sci 123: 108–113.

12. White JD, Davies M, Grounds MD (2001) Leukemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: combined in vivo and in vitro studies in post-natal skeletal muscle. Cell Tissue Res 306: 129–141.

13. White JD, Bower J, Kurck JR, Austin L (2001) Leukemia inhibitory factor enhances regeneration in skeletal muscles after myoblast transplantation. Muscle Nerve 24: 695–697.

14. Kook SH, Son YO, Lee KY, Lee HJ, Chung WT, et al. (2008) Hypoxia affects 1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395–403. S109727650002114 [pii].

15. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, et al. (2009) Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differ-